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Antlgenic site A of foot-and-mouth disease virus (FMDV) is an exposed, mobile loop which Includes a central, highly conserved Arg-Gly-Asp 
tripeptide (RGD, VP1 residues 141-143 m serotype C) thought to be part of the cell attachment site. We have analyzed the contribution of RGD 
to the interactlon of site A with antlbodies by incorporating selected ammo acid replacements at RGD into synthetic peptides representmg site 
A, and analyzing the reactivity of substituted peptides with site A-specific monoclonal antibodles (MAbs). Replacement of Arg-141, Gly-142 or 
Asp-143 by alanine resulted m the loss of one, three and five epltopes. respectively. out of seven epitopes probed. Other replacements resulted in 
the loss of even larger numbers of epitopes, suggesting that the amino acids of the RGD region are either directly involved in interaction with 
antibodies or that they exert an important influence on the interaction of surrounding residues with antlbodies. Thus, we explored the abihty of 
tandem repeats of the RGDL sequence (corresponding to FMDV C-S8cl) to evoke neutrahzmg antibodies in rabbits and guinea pigs. Neutralizing 
activity was generally low but with a broad specificity for different FMDV serotypes and variants. Significant decreases in neutralizing titers were 
observed with boosting, suggesting a possible suppression of those anti-peptide antibodies which may also be dnected to cellular RGD sequences. 
The results point to an mvolvement of RGD in the antigemc structure of site A, and open the possibility that broadly neutralizing antibodies might 
be induced by tandem repeats of the critical. conserved domain. 
Immunopeptlde; RGD: Cross-neutralization; Antlgemc varlabllity 
1. INTRODUCTION 
Foot-and-mouth disease virus (FMDV), responsible 
for the economically most important viral disease of 
cattle and other cloven-hooved animals [l-3], shows 
extreme genetic variability and antigenic diversity, as do 
most other RNA viruses [3-71. Analysis of the reactivity 
of monoclonal antibodies (MAbs) with FMDV has 
shown that a few capsid regions, which include multiple 
overlapping epitopes, are involved in virus neutraliza- 
tion [3,8-l 11. The main antigenic site of FMDV (site A) 
is a flexible loop on protein VP1 exposed on the virus 
surface [12,13]. B-cell epitopes located on ehis site A 
(VP1 residues 138-150 in serotype C, isolate C-$3~1) 
map at residues surrounding a conserved RGD tripep- 
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tide (residues 141-143) [3,10] thought to be a cell-at- 
tachment site [14]. Serotypes C, most type 0, and some 
type A viruses also show a conserved Leu at position 
144 (Table I). 
Frequent amino acid substitutions occur within anti- 
genie site A of field FMDV variants and of laboratory 
mutants, including antibody-escape mutants. The effect 
of observed amino acid replacements within site A on 
the reactivity of FMDV C-SK1 with MAbs has been 
faithfully reproduced by synthetic peptides which in- 
cluded the relevant substitutions [15]. The extremely 
variable sequences at positions 138-140 and 146-150 
seem to attract immune responses which might be de- 
toured from RGDL [3,7]. The practical absence of mu- 
tants in this RGDL region is a significant hurdle to the 
assessment of its contribution to the overall immuno- 
genicity and antigenicity of site A. We have approached 
this problem by evaluating the effect of replacements at 
each of the three positions of the RGD tripeptide on the 
interaction of synthetic peptides with MAbs. We have 
also evaluated the immune response of rabbits and 
guinea pigs to several synthetic peptides composed of 
three RGDL tandem repeats. Our results show that the 
RGD tripeptide is an important determinant of the in- 
teraction of antigenic site A with antibodies, and that 
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a significant anti-peptide and FMDV-neutralizing re- 
sponse can be obtained with peptides based on RGD. 
However, a potent neutralizing anti-viral response re- 
quires the highly variable residues surrounding the 
RGD. Appropriate combinations of peptides represent- 
ing most residues of site A. along with tandem repeats 
of the conserved residues around the RGD core, may 
be useful in the formulation of anti-FMDV synthetic 
vaccines with broader antigenic spectra than formula- 
tions assayed so far [l&18]. 
2. MATERIALS AND METHODS 
‘. 1. Cdls und I’IYUSCS 
Procedures for cell culture were as previously described [19]. Viral 
antigens were prepared by FMDV mfectlon of BHK-c2 cell monolay- 
ers. and recovered virus was partially purified by sedlmentatlon 
through a sucrose cushion [20]. FMDV from three serotypes were 
utilized: C-S8cl (Cl Santa Pau: Spain. 1970. wild type and Its MAb 
SD6-resistant mutant HR [I I]]. A,-Westerwald and O,-Kaufbeuren 
Thkpeptldes used in this study ware shown m Table II. The) were 
synthesized as C-termmal carboxamldes by solid-phase procedures 
[21,22]. as recently described [15]. A Cys residue was added to the 
C-terminus of all sequences to allow conJugat]on to carriers. After HF 
cleavage and deprotection. purification was done by reverred-phase 
liquid chromatography on C,,-silica using linear acetomtnle-mto- 
water gradients (both sohents contammg 0.1% tnfluoroacetlc acid 1. 
Fractions of satisfactory (> 95%) purity by HPLC were pooled and 
characterized by amino acid analysis (6 N HCI. 110°C. 23 h) and 
electrospraq mass spectrometry. Peptldes were coupled to keyhole 
limpet hemocyanin (KLH) through MBS [33] for Immunizatlom or to 
BSA through SPDP [24] for lmmunologlcal assays. 
Two rabbits (New Zealand or Blanc0 Buscat) were immumzed alth 
400 pug of RGDL peptldes coupled to KLH m complete Freund ad- 
juvant. Boosting was carried out with the same amount of peptide in 
incomplete Freund adjuvant three times every three weeks, except for 
rabbits receiving RGDL, and RGDL,X, which were boosted only 
twice. Animals were bled before the first maculation and 10 days after 
each inoculation, and the sera obtained were kept at -70°C untd use. 
The same protocol was followed with two to 51x Dunkin HartIs) 
guinea pigs. except that peptide A24 was included as a control. and 
the amount of peptide maculated was 200 pug of RGDL,AA and the 
equivalent molar amounts of the other peptides. Sera were labeled s,. 
n being the number of moculatlons received before bleeding. Immu- 
noglobuhns of s, and s1 samples (2 ml) were concentrated with 50% 
ammonium sulfate, resuspended m 0.5 ml PBS and loaded on a Se- 
Table I 
Sequence alignment of residues 136-l 5 1 of FMDV isolates 
Virus FMDV loop” 
C-S8cl 'l"YTASA....RGDLAHLTT"H" 
HR YTASA....RGDLhF.LTTTH 
01-K YIJRI~ATjPIILRGDLOVL~~QKV 
A5-W 'fSTGCP..RRGDMGSAdARA 
' Dots represent amino acid deletions needed to align the sequences 
keepmg the conserved Y(l36) and the RGD motif at equivalent 
positions. 
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Table II 
Synthetic peptldes” and their carrier protein conjugates 
Peptide Amino acid sequence’ MW’ Peptlde- 
carrier 
protem ratio” 
RGD(A19) 
AGD 
KGD 
SGD 
RAD 
RED 
RCA 
RGK 
RGE 
HR \i 
AFARGDLAHLTTTHARHLP 
ASAAGDLAHLTTTHARHLP _ 
ASIKGDLAHLTTTHARHLP 
AS.k~GDLkHT,T?THARHLP 
ASAGDLAHLTTTHARHLP 
kSARiDLAHLTTTHAF.HLP 
ASARGALAHLTTTHARH;P 
ASARGiiLkHLTTTHAPHLP _ 
ASARGELAHLTTTYARHLF _ 
TASARGDLhRLTTTHARHLt 
KLH BSA 
2033.7 7 
1938.6 
19?5 7 
1954.6 
2037.7 
2081.7 
19797 
7036.8 
7037 7 
2307.0 
A24 TTTYThS.SRGDLAHLTTTH4F.HLP.C 2768.0 740 
RGDL,AXA C ARGDLASARGDLAXARGDLA 2099.2 2775 18 
RGDL,AA Cl:ARGDLA. ARGDLA ARGDLA 1971.7 2413 15 
RGDL,A C RGDL.q. . RGDLA. . RGDL 1588.2 3003 15 
RGDL,X C..RGDLM..RGDLS..RGDL 1672.6 1130 15 
RGDL, C RGDL...RGDL...RGDL 1446.0 3504 16 
MW values of 5 x lOh and 67.000 for KLH and BSA. respectively. 
were used in the calculations 
’ X=E aminohexanolc acid. 
h Some peptides carry an addItIona Cys residue at the N- or C-termi 
nus to allow specific conJugatlon to the carrier Underlmed residues 
Indicate replacements in the orlgmal sequence of site A. 
’ Calculated molecular weight m Da. For all peptides, mass spectra 
gave the expected MW values (f Da). 
“Determmed by amino acid analysis of conjugates after extensive 
dlalysls. 
phadex G-200 column (75 x 1 6 cm) Proteins were eluted with PBS 
(20 ml/h) and 3 ml-fractions were collected and subjected to PAGE 
to determine those correspondmg to IgG and IgM. Samples were 
pooled, concentrated with 50% ammonium sulfate. resuspended m 0.5 
ml PBS and dialyzed agamst PBS. 
Enzyme-lmked lmmunodot (EID) and enzyme-linked Immunoelec- 
trotransfer blot (EITB) protocols were as described [19]. except that 
MAbs were replaced by sera at ~anous dllutlons. and goat an&mouse 
IgG-peroxidare by goat anti-rabbit IgG (H+L)-hor,eradlsh peroui- 
dase (Blo-Rad. 1 2.500 dilution. 1 h. r t.) or goat-anti-guinea pig 
(H+L)-horseradish pcroxldase (Nordic. 1 1.000 dllutlon. I h. r.t.). 
For the antigen competition assays with peptldes substituted at RGD. 
ELISA plates were coated with 5 pmol of peptide Al9 (Table II) 
coupled to KLH. incubated ovcrmght at 4°C and saturated with 5% 
BSA Ml\tures of a filed non-saturatmg amount of MAb and variable 
amounta (1.5. 5, 15. 45. 135. 405 and 1215 pmol) ofcompetltor pep- 
tides (m 0.5% BSA in PBS) \vere premcubated for 2 h at r.t.. added 
to the ELISA plates and further incubated for 1 hat r.t After washing 
with 0.05% Tween 30, 0 1% BS.4 m PBS. peroxldabe-conJu_e;ted goat 
anti- mouse IgG (Blo-Rad. 1:3,000 dllutlon) wab added and Incubated 
for I h at r.t. The plates were thoroughly washed with 0 05% Twecn 
30.0.1% BSA in PBS. and the reaction developed usmg o-phenylenedl- 
amine as a substrate. Absorbance wac read at 492 nm 
Neutrahzatlon of infectlvlty was performed on BHK-c2 cell mono- 
layers after mcubatlon of sera or fractionated Ig ddutlons with virus 
as described [19]. except that ncutrahzatlon values are expressed as 
plaque reduction percentage (PRP). 
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Fig. 1. Antigen-competition assay of monoclonal antibody SD6 and selected peptides 
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3. RESULTS 
3.1. Reactivity of antibodies with FMD Vpeptides substi- 
tuted at the RGD domain 
To explore the possible contribution of the RGD 
tripeptide to the interaction of antigenic site A with 
antibodies we replaced each of the three residues by Ala 
in synthetic peptides comprising VP1 residues 138 to 
156 of VP1 of FMDV C-Sk1 (Table II). We chose to 
study the binding to substituted peptides of seven MAbs 
that recognize different continuous epitopes located 
within site A [10,11,19,20]. An antigen competition 
ELISA was used, in which KLH-conjugated peptide 
Al9 was attached to plates and the binding to MAbs 
Table III 
Antigen-competltlon ELISA with RGD-substituted peptides 
Monoclonal antibod) 
Peptide SD6 4C4 6Dll 7FC12 7AHl 7JDl 7CAll 
RGD(A19) + + + + + + + 
AGD + + _ + + + + 
RAD + + + _ + 
RGA _ _ _ + + 
SGD + - _ + 
KGD _ _ _ + + 
RED - - - - _ 
RGK _ _ _ + + 
RGE - - - _ _ + + 
HR _ _ 
Amino acid sequences of the peptldes are shown m Table II. Compe- 
titlon ELISA was performed as described m section 2. + Indicates that 
a ZO-fold molar excess of the competing antigen over plate-bound 
peptide Al9 caused an Inhibition in Mab binding greater than 30%;; 
- indicates that such inhlbition was lower than 30%: f mdlcates 
inhIbitIon close to 30%. 
was quantitated in the presence of increasing concentra- 
tions of the free peptide to be tested. The results ob- 
tained with one of the MAbs (SD6) are shown in Fig. 
1. The complete results (Table III) show that tolerance 
to replacement by alanine was greatest for Arg-141, 
resulting in the loss of only the epitope defined by MAb 
6Dll. In contrast, Asp-143 was the least tolerant to Ala 
replacement. with only two of the probed epitopes re- 
maining positive. To test whether amino acids other 
than Ala, in particular those leading to gross side chain 
and/or charge alteration and that could occur as a result 
of a point mutation of the C-S8cl nucleotide sequence. 
resulted in comparable or different antigenic modifica- 
tion. several additional substituted peptides were tested 
in the same competition ELISA (Fig. 1 and Table III). 
Any of the replacements resulted in a larger alteration 
of MAb recognition than that caused by Ala. In partic- 
ular, the presence of Glu at position 142 led to loss of 
all epitopes probed, an alteration as drastic as that in- 
duced by the His-146+Arg replacement [11,25]. Thus, 
each of the amino acids in the RGD triplet has an 
important contribution to the recognition of site A by 
antibodies. 
3.2. Imnunogenicit~~ oj’ peptides containing tandem re- 
peats qf the RGDL sequence 
Since the RGD sequence is involved in the recogni- 
tion of antigenic site A by antibodies. we considered the 
possibility that synthetic peptides based on such se- 
quence could induce neutralizing antibodies which 
might define a broader antigenic spectrum than pep- 
tides involving variable residues around RGD. We 
chose to build synthetic peptides made of tandem re- 
peats of the basic unit RGDL because Leu-144 is strictly 
conserved in all type C viruses sequenced to date and 
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Ftg. 2. Reactivity of synthetic peptide (RGDL,X) m&ding the RGD sequence with sera raised agamst homologous peptide (rabbtt 742). Thus result 
is representattve for both rabbits and gumea-ptgs, except that the latter showed lower anti-KLH responses. s. are sera extracted 10 days after 
immumzation number n (see sectton 2). Antigens applied to nitrocellulose were a and f. PBS; b, KLH (4.4 x IO-’ pmol, amount equivalent to that 
m 5 pmol of the corresponding conjugate), c. KLH (4.4 x IO-’ pmol): d. pepttde RGDL,X (5 pmol): e. pepttde RGDL?X (50 pmol). Sera dilutions 
are mdtcated 
in nearly all type 0 isolates [7]. Table I shows the amino 
acid sequence alignment of the FMDV loop of represen- 
tatives of FMDV serotypes C. 0, and A. The RGDL 
repeats were separated by different spacer residues as 
shown in Table II. Anti-peptide antibody titers in rab- 
bits and guinea pigs were generally high. A representa- 
tive EID assay is shown in Fig. 2. All sera reacted with 
heterologous RGDL-containing antigens. though to a 
much lesser extent than with the homologous peptide 
(not shown), suggesting a low proportion of antibodies 
with RGDL as the sole target. As expected, the first 
boost improved anti-peptide antibody levels, though 
further inoculations had no effect. Some sera reacted 
with entire FMDV C-Sk1 and/or its HR mutant, but 
with other sera this reaction was not observed. EITB 
did not show which was the viral protein recognized by 
anti-peptide antibodies, even when highly concentrated 
sera (1 : 4 dilution) were used, again suggesting that 
RGDL was too short a target for efficient binding to 
antibodies. 
3.3. FMDV neutralization bl- unti-peptide sera 
Anti-peptide sera were tested for their ability to neu- 
tralize C-S&l FMDV (Table IV). Values showed con- 
siderable variation depending on the peptide antigen 
and the individual animal inoculated. Even the highest 
neutralization values (PRP = 74 for guinea pig 1 at 1:5 
dilution and 78 for rabbit 747 at 1:20 dilution) were two 
to three orders of magnitude lower than those attained 
with anti-peptide A24 sera. In spite of the mentioned 
variations, neutralization values for rabbits and guinea 
pigs were of the same order. Dilutions higher than I:20 
rendered undetectable levels of specific neutralization. 
No correlation was found between viral particle recog- 
nition by EID and neutralizing ability. In most animals, 
neutralizing values dropped significantly with the num- 
ber of boosts. To study the underlying phenomenon, 
IgGs and IgMs corresponding to s, and sj of rabbit 740 
(s,PRP = 70, s,PRP = 20) were fractioned and assayed 
for their neutralization ability. Only the IgM fraction of 
s1 was found to neutralize C-S&l to a significant extent 
(PRP = 58%). 
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Neutralizing activity elicited in rabbits was higher for 
peptides including more amino acids of the consensus 
C-S8cl sequence. Guinea pig sera gave better results 
when shorter peptides were used as immunogens. An- 
other difference. which might be significant, between 
the two animal systems was the effect of including E- 
aminohexanoic acid as a spacer. Comparison of results 
obtained with the RGDL,/RGDL,X and RGDL,AA/ 
RGDL,AXA pairs is illustrative: in rabbits, no differ- 
ences were found among sera against peptides with or 
without .r+aminohexanoic acid, while in guinea pigs neu- 
tralizing activity was completely lost when this amino 
acid was present as spacer in the immunogen (Table IV). 
In addition to C-S8c1, two representatives of other 
serotypes (FMDV O,-Kaufbeuren and A,-Westerwald) 
were also tested for cross-neutralization by the anti- 
peptide sera. Again, low but significant neutralization 
was noted with several of the tested sera. It must be 
emphasized that peptide A24, which includes the 
RGDL sequence surrounded by serotype-specific C se- 
quences. did not induce any detectable neutralizing ac- 
tivity against 0,K or A,W (Table IV). It is also note- 
worthy that mutant HR. resulting from the His- 
146-+Arg substitution in VPl, and which led to the loss 
of all tested site A epitopes involved in neutralization of 
infectivity [10,25]. was neutralized at least as efficiently 
as its wild-type counterpart C-S8cl (Table IV). These 
results point to a relaxation of the specificity of the 
immune response against FMDV when sequences re- 
sponsible for serotype specificity are excluded from the 
peptide immunogens. However, encephalomyocarditis 
virus (EMCV). the phylogenetically closest relative to 
aphthoviruses, was not neutralized to any extent by 
each serum tested (Table IV). 
We therefore conclude that the highly conserved 
RGD tripeptide located within antigenic site A is an 
important determinant of the interaction of site A with 
neutralizing antibodies. Peptides based on tandem re- 
peats of the RGDL tetrapeptide were capable of induc- 
ing neutralizing antibodies with highly relaxed serotype 
and variant specificity. Although the neutralization lev- 
els were low. the observations reported in this paper 
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Table IV 
Neutralizing ability of anti-RGDL peptide sera 
Peptide Animal Virus* 
C-S8cl HR 0,K A,W EMCV 
A. Guinea pigs 
RGDLxA 
RGDL,X 19 0 4.5 0 2.3 ND 
20 8.9 27.5 25 9 12.9 ND 
RGDL,AXA 21 0 0 25.9 0 ND 
22 0 42.4 16.8 0 ND 
A24 23 100 100 0 0 ND 
23’ 66.1 33.9 0 0 ND 
24 100 100 0 0 ND 
24’ 55.3 76.6 0 0 ND 
RGDL, 1 74.3 45.0 20.6 324 
2 47.5 97.6 33 9 38.3 
3 70.5 66.1 83.8 24 1 
4 72.5 92.7 56.3 8.9 
5 43.8 80.9 8.9 0 
6 29.2 47.5 0 0 
Mean 56 3 71.6 33 9 17.3 
7 70.5 88.0 8.9 42.4 
8 62.0 59.3 32.4 0 
9 48.7 95.2 4.5 0 
10 35.4 90.4 6.7 65.3 
11 30.8 95.2 0 4.5 
12 36.9 90.4 0 187 
Mean 474 86.4 8.6 21.8 
RGDL,AA 13 22.4 76.0 8.9 56.3 
14 20.6 73.7 10.9 69 1 
15 39.7 95.2 22.4 65 3 
16 56.3 80.9 2.3 30.8 
17 0 88.0 0 16.8 
18 10.9 20.6 0 0 
Mean 250 72.4 74 397 
RGDL, 
RGDL,A 
RGDL,AA 
RGDL,X 
RGDL,AXA 
B. Rabbits 
144 
145 
132 
738 
746 
747 
742 
743 
739 
740 
16.8 27.5 9.0 0 ND 
47.5 73 7 76.0 0 ND 
51.0 84.5 0 4 5 0 
80.9 100 0 4.5 ND 
93.4 95.1 0 0 ND 
89.3 96.6 0 0 ND 
20.6 38.3 0 6.7 ND 
30.8 66.1 14.9 0 ND 
77.1 97.5 14.9 6.7 ND 
62.8 77.6 6.7 6.7 ND 
NDb 
ND 
0 
ND 
0 
ND 
ND 
0 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
< 2.5 
“Values are given as plaque reductton percentage (PRP) of si dtluted 
1:5 and 1:4 for rabbits and guinea pigs, respectrvely. 
‘ND = not determined. 
‘PRPs comparable to those obtained for 1:s dilution, which corre- 
sponded to a 1:6250 dilutton. 
open the way to engineer synthetic constructs capable 
of inducing broader antiviral immune responses than 
peptides based on the authentic amino acid sequences 
of natural isolates. 
4. DISCUSSION 
Previous studies have shown that neutralizing anti- 
FMDV activity can be induced by peptides correspond- 
ing to the 140-160 VP1 loop [16-181, but the possible 
implication of the conserved RGD( L) residues in recog- 
nition of antigenic site A by neutralizing antibodies has 
not been established, except for one reported case of 
G+E substitution in serotype A which conferred resis- 
tance to one neutralizing MAb [8]. The implication of 
RGD in antibody binding has been investigated by min- 
imally disrupting the peptide sequence, and presumably 
the peptide chain conformation, as a result of single 
substitutions by Ala [26]. Severeal epitopes were lost, 
most of them as a result of a replacement of Asp-143 
(Table III). Other more drastic replacements involving 
charge alterations resulted in the loss of additional epi- 
topes (Table III). Our previous observations [10,15] 
have firmly establised that synthetic peptides represent- 
ing antigenic site A of FMDV C-W1 faithfully mimic 
the behaviour of entire virus particles in their interac- 
tion with antibodies. It may be significant that the epi- 
topes defined by MAbs 7CAll and 7JD1, which were 
mapped to the carboxy-side of RGD by analysis of 
escape mutants and binding to peptides [l 11, were the 
least affected by replacements at the RGD tripeptide 
(Table 111). Each of the other MAbs tested mapped at 
both sides of RGD, suggesting that this tripeptide is 
either directly involved in interactions with the MAbs 
or participates in delineating the local conformation(s) 
recognized by MAbs. The effect of Ala replacements 
would seem to favor the first interpretation. 
The involvement of RGD in antibody binding raised 
the possibility that such a sequence could become the 
target of an induced immune response with the added 
advantage that the conservation of RGD could circum- 
vent the serious problem of antigenic variation of 
FMDV [3,6.19,20,25]. Perhaps not unexpectedly, these 
predictions have met with only partial success. Antibod- 
ies raised against tandem repeats of the RGDL 
tetrapeptide bound effectively homologous peptides 
and to a lesser extent the heterologous peptides. How- 
ever, their ability to neutralize virus was limited (Table 
IV). It should be noted that the RGD sequence is the 
binding site of the integrin superfamily [27], which in- 
cludes a variety of widely distributed proteins involved 
in cell adhesion. Although the residues surrounding 
RGD are important for recognition. peptides contain- 
ing or mimicking the RGD motif can inhibit platelet 
aggregation [28,29]. so that it cannot be ruled out that 
the immune system could limit the anti-RGD antibody 
production for self tolerance. The structure of the VP1 
G-H loop of FMDV C-SScl, where antigenic site A is 
located, is not known. However, the RGD in a reduced 
form of FMDV 0,BFS has been recently elucidated 
[13]. In this chemically modified virus the RGD tripep- 
tide acquires a conformation very similar to y-ll-cris- 
tallin and probably also to other integrin-binding pro- 
teins. Thus, it is not unlikely that the spatial arrange- 
ment adopted by RGD on the C-%1 virion surface 
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might show some similarity to integrin-binding sites in 
several proteins. Indeed, our finding that neutralizing 
activity is essentially confined to IgMs strongly suggests 
that auto-antibodies (normally belonging to the M 
isotype [30]) are produced at an early stage of the im- 
mune response and later suppressed, thus preventing 
the switch to IgGs from lymphocyte clones recognizing 
both self antigens and FMDV virions. Dilution of the 
incipient IgM populations may be assumed to take 
place by selection and amplification of clones recogniz- 
ing other RGD conformations present in our peptides. 
This would explain the fact that peptide recognition 
improvements were observed concomitant to decrease 
or even complete loss of neutralizing ability. 
Other reasons could also contribute to the low neu- 
tralizing responses. First. tandem repeats include epi- 
topes not present in the virus (e.g. LAXAR for 
RGDL,AXA, etc.), which could induce anti-peptide but 
not anti-virus response. On the other hand. the RGDL 
tandem repeat peptides could adopt multiple conforma- 
tions capable of inducing antibodies not recognizing the 
native conformation on the virus surface. Furthermore, 
the rather short length of the 4-6 residue target could 
provide insufficient anchoring points for antibodies. 
which would clearly limit the immunogenicity and anti- 
genicity of the sequences despite their presentation as 
tandem repeats. The relatively poor results observed for 
&-aminohexanoic acid-containing repeats could be attri- 
buted to the enhanced structural mobility conferred by 
this residue [3 11. resulting in the induction of antibodies 
against neutral or unfavourable conformations. 
Of particular interest are the results of mutant HR 
neutralization. This variant [ 11,251 is resistant to MAbs 
directed to site A and it is neutralized less efficiently 
than its parental C-S&l by polyclonal sera. However. 
our data suggest that the His-146+Arg replacement 
does not significantly affect the RGDL conformation, 
as shown by the fact that peptides that elicited specific 
neutralizing activity were cros-reactive. 
The danger of inducing FMDV outbreaks due to 
handling of live virus or improper inactivation of anti- 
gens [32] has stimulated the search for vaccines based 
on synthetic peptides 133.341. Peptides derived from site 
A have been shown to elicit a protective response 
against FMDV in guinea pigs and cattle [16-l 81 and in 
some cases some evidence of cross-protection has been 
presented [35]. However, the use of these peptides may 
not necessarily provide coverage against many co-circu- 
lating variants. This problem might be eventually atten- 
uated with anti-FMDV vaccine formulations that in- 
clude peptides reproducing conserved sequences, so that 
cross-reactive response to variants would be favoured. 
In spite of the limited success of this initial attempt. the 
results show that a neutralizing response against a 
broad spectrum of variants is possible. Choice of appro- 
priate adjuvants as well as the inclusion of tandem- 
repeated peptides with a few additional residues sur- 
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rounding the RGD tripeptide may evoke the induction 
of immune response with greater neutralization poten- 
tial yet maintaining a relaxed specificity to cause neu- 
tralization of many variants able to escape antibodies 
directed to authentic site A. 
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